BiVictriX Therapeutics Plc announced that it has appointed Adrian Howd, PhD as Chief Business Officer. Adrian joins BiVictriX with over 20 years of strategic financial and commercial experience in the biopharmaceutical industry, having held various financial roles, private and public executive management positions and board roles across the sector. During his career to date he has led multiple asset and corporate business development transactions, as well as numerous equity capital market fundraises totaling over ?430 million.

Adrian possesses substantial equity capital markets experience in the UK and overseas, gained during his previous senior roles at Berenberg Bank, ABN Amro and Nomura. Adrian has also held various senior management roles, including Chief Investment Officer and Chief Executive Officer at investment firm, Malin plc, where he led the Company to its debut on the Irish Stock Exchange in one of the largest European life science initial public offerings to date. At Malin, Adrian led investments in and served on the boards of both Immunocore and Kymab, two "platform to therapeutic" UK-based companies, both of which achieved multibillion USD exits via a NASDAQ IPO and a trade sale to Sanofi respectively.